Patient monitoring and follow-up in lentiviral clinical trials

Journal of Gene Medicine

Volumn 15, Issue 2, 2013, Pages 78-82

  McGarrity, Gerard J ^a   Hoyah, Gloria ^a   Winemiller, April ^a,h   Andre, Kris ^a   Stein, David ^b   Blick, Gary ^c   Greenberg, Richard N ^d   Kinder, Clifford ^e   Zolopa, Andrew ^f   Binder Scholl, Gwen ^g,i   Tebas, Pablo ^g   June, Carl H ^g   Humeau, Laurent M ^a   Rebello, Tessio ^a  

^a VIRxSYS Corporation   (United States)

^b JACOBI MEDICAL CENTER   (United States)

^c Circle Medical Center ^*  (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e Kinder Medical Group   (United States)

^f STANFORD UNIVERSITY   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ Adaptimmune Ltd   (United Kingdom)

Author keywords

Clinical trials; Lentiviral vectors; Safety monitoring

Indexed keywords

LEXGENLEUCEL T; VIRUS DNA;

ANTISENSE THERAPY; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; VESICULAR STOMATITIS VIRUS;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; GENETIC THERAPY; GENETIC VECTORS; HIV-1; HUMANS; MEMBRANE GLYCOPROTEINS; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84874354091     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2691     Document Type: Article

References (18)

1. Levine BL, Humeau L, Moyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006; 103: 17372-17377.
2. Pauwels K, Gijsberg R, Toelen J, et al. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. Curr Gene Ther 2009; 9: 459-474.
3. Hematti P, Hong BK, Ferguson C, et al. Distinct genomic integration of MLV and SIV vectors in primate haematopoietic stem and progenitor cells. PLoS Biol 2004; 2: e423.
4. Baum C, Kustikova O, Medlich U, et al. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 2006; 17: 253-263.
5. Gene Therapy Clinical Trials Worldwide. 2012. http://www.wiley.com/legacy [January 2012].
6. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
7. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
8. Anderson WF, McGarrity GJ, Moen RC. Report to the NIH Recombinant DNA Advisory Committee on murine replication-competent retrovirus (RCR) assays. Hum Gene Ther 1993; 4: 311-321.
9. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumour-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696.
10. Schonely K, Afable C, Slepuskin V, et al. QC release testing of an HIV-1 based lentiviral vector lot and transduced cellular product. Bioprocess J 2003; 2: 39-47.
11. Bear AS, Morgan RA, Cornetta K, et al. Replication-competent retroviruses in gene modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther 2012; 20: 246-249.
12. Food and Drug Administration. Supplemental Guidance on Testing for Replication Competent Retrovirus in Retroviral Vector Bases Gene Therapy Products and During Follow-up of Patients in Clinical Trials using Retroviral Vectors. Food and Drug Administration: http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/cellularandgenetherapy/ucm072961.htm, 2006; 1-15.
13. Wang GP, Levine BL, Binder GW, et al. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol Ther 2009; 17: 844-850.
14. Long Z, Lu P, Grooms T, et al. Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy. Hum Gene Ther 1999; 10: 733-740.
15. Biffi A. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011; 117: 5332-5339.
16. Knight S, Bokhoven M, Collins M, Takeuchi Y. Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long-terminal repeat. J Virol 2010; 84: 4856-4859.
17. Clonal Population of Cells Detected in a Clinical Gene Transfer Study Using a Lentiviral Vector: Press Release June 10, 2009. http://oba.od.nih.gov/oba/RAC/News/Memoto%20Investigators%20%20June%20_10%20final.pdf [12 July 2009].
18. RECOMBINANT DNA ADVISORY COMMITTEE. Minutes of Meeting December 1-2, 2009. http://oba.od.nih.gov/oba/rac/meetings/dec2009/rac_minutes_12-09.pdf [26 September 2010].